Aura Biosciences (NASDAQ:AURA) Releases Earnings Results

Aura Biosciences (NASDAQ:AURA – Get Rating) released its quarterly earnings data on Wednesday. The company reported ($0.52) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.06, Yahoo Finance reports.

Aura Biosciences Stock Up 0.3 %

AURA stock opened at $10.21 on Friday. Aura Biosciences has a fifty-two week low of $9.43 and a fifty-two week high of $24.83. The firm’s 50-day simple moving average is $10.55 and its 200 day simple moving average is $12.30.

Wall Street Analyst Weigh In

Separately, JMP Securities dropped their price objective on shares of Aura Biosciences from $30.00 to $25.00 and set an “outperform” rating on the stock in a report on Thursday.

Insider Buying and Selling

In related news, Director David Michael Johnson bought 4,000 shares of the firm’s stock in a transaction that occurred on Wednesday, December 28th. The stock was purchased at an average price of $9.75 per share, for a total transaction of $39,000.00. Following the transaction, the director now directly owns 17,000 shares of the company’s stock, valued at approximately $165,750. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 5.00% of the company’s stock.

Hedge Funds Weigh In On Aura Biosciences

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Morgan Stanley grew its position in Aura Biosciences by 17.1% in the 4th quarter. Morgan Stanley now owns 64,603 shares of the company’s stock valued at $678,000 after buying an additional 9,451 shares in the last quarter. Alps Advisors Inc. bought a new position in shares of Aura Biosciences during the 4th quarter valued at about $257,000. Alyeska Investment Group L.P. bought a new position in shares of Aura Biosciences during the 4th quarter valued at about $225,000. Price T Rowe Associates Inc. MD bought a new position in shares of Aura Biosciences during the 4th quarter valued at about $7,762,000. Finally, Renaissance Technologies LLC bought a new position in shares of Aura Biosciences during the 4th quarter valued at about $138,000. Institutional investors own 55.63% of the company’s stock.

Aura Biosciences Company Profile

(Get Rating)

Aura Biosciences, Inc operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma.